Key Market Drivers, Trends, and Forecast for the Global RNA Targeting Small Molecules Therapeutics Industry
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the RNA Targeting Small Molecules Therapeutics Market Heading Into 2029?
The market size of RNA targeting small molecules therapeutics has witnessed a substantial surge in the past few years. There’s an expected leap in its value from $6.1 billion in 2024 to a whopping $7.83 billion in 2025 showing a compound annual growth rate (CAGR) of 28.3%. The phenomenal growth in the market during this historical period can be credited to the progress in drug discovery and development, an increase in RNA-related diseases, funding provided by the government and private bodies, vested interest of the pharmaceutical industry, and the previous successes in the field of RNA therapeutics.
The market size for RNA targeting small molecules therapeutics is anticipated to witness substantial growth in the coming years. It is projected to reach $21.95 billion by 2029, seeing a compound annual growth rate (CAGR) of 29.4%. Factors contributing to this growth in the forecast period include precision medicine and personalized therapies, increase in RNA biomarker identification, the expansion of the RNA target spectrum, rising funding and investments, and its application in rare diseases. In the forecast period, significant trends include advancements in screening technologies, the dominance of antisense oligonucleotides, small molecule RNA binders, the use of RNA therapeutics in treating neurological disorders, and gene editing with crispr-cas9.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp
Which Factors Are Pushing The RNA Targeting Small Molecules Therapeutics Market Forward?
The growth of the RNA-targeting small molecule therapeutics market is anticipated to be spurred by the escalating occurrence of cancer cases. Cancer comprises a range of diseases that may arise in virtually any organ or tissue when rogue cells grow without restriction, breach their normal limits, and either disseminate to other organs or infiltrate adjacent body parts. RNA-targeting small molecules, specifically designed and examined for selectively targeting RNA molecules tied to cancer, are used to treat this disease. A notable example is a study published by the American Cancer Society, a health organization based in the US, in January 2022. The report predicted approximately 609,360 deaths and 1.9 million fresh cancer cases in the US in 2022, which equates to around 1,670 deaths per day. As such, the proliferating count of cancer cases is seen as a key driver for the expansion of the RNA-targeting small molecule therapeutics market.
Which Segment Held The Largest Share In The RNA Targeting Small Molecules Therapeutics Market In 2025?
The rna targeting small molecules therapeutics market covered in this report is segmented –
1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings
2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications
3) By Application: Drug Discovery, Oncology Research, Disease Identification
4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation
2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides
3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers
4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability
How Are Key Trends Driving Expansion In The RNA Targeting Small Molecules Therapeutics Industry?
One major trend that is gaining considerable traction in the retinal biologics market is product innovation. Major players in this market are focusing on designing novel products as a strategy to solidify their market position and obtain a competitive edge. For example, in May 2023, F. Hoffmann-La Roche Ltd., a Swiss healthcare organization, received approval from the U.S. Food and Drug Administration for its supplemental biologics license application (sBLA) for Vabysmo (faricimab). This approval was granted for the treatment of macular edema following retinal vein occlusion (RVO), based on the results of two Phase III trials. These trials demonstrated early and substantial visual improvement in patients using Vabysmo, achieving its primary operative endpoint of being as effective as aflibercept. Vabysmo stands as the inaugural bispecific antibody approved for ocular use, particularly for treating neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Subsequent research showed a lack of blood vessel leakage in the retina in patients using Vabysmo compared to those using aflibercept.
Which Organizations Are Driving Progress In The RNA Targeting Small Molecules Therapeutics Industry?
Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics
Get The Full Report Here:
Which Region Is Expected To Experience The Highest Growth In The RNA Targeting Small Molecules Therapeutics Industry?
North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
